Cabaletta Bio Inc. is a clinical stage biotechnology company. It is focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's product pipeline consists of DSG3-CAART, DSG3/1-CAART, MuSK-CAART and FVIII-CAART which are in clinical stage. Cabaletta Bio Inc. is based in Philadelphia, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-115.86M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.80 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -78.29% |
| Return on Assets (Trailing 12 Months) | -65.68% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.96 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.96 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $2.40 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.71 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.34 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.54 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.74M |
| Free Float | 45.03M |
| Market Capitalization | $96.92M |
| Average Volume (Last 20 Days) | 2.28M |
| Beta (Past 60 Months) | 2.72 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.25% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |